Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial (Q33417762)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Ashraf Elghandour

object named as

Ashraf Elghandour

6

0 references

object named as

Monika Sopala

41

0 references

object named as

Hans Salwender

24

0 references

object named as

Enrique M Ocio

35

0 references

object named as

Hareth Nahi

22

0 references

Javier de la Rubia

object named as

Javier de la Rubia

31

0 references

Krzysztof Warzocha

object named as

Krzysztof Warzocha

27

0 references

Paolo Corradini

object named as

Paolo Corradini

11

0 references

Athanasios Dimopoulos

object named as

Meletios Athanasios Dimopoulos

5

0 references

33

object named as

Sagar Lonial

1 reference

Europe PubMed Central

26 July 2017

Hermann Einsele

40

object named as

Hermann Einsele

1 reference

Europe PubMed Central

26 July 2017

Paul G. Richardson

45

object named as

Paul G Richardson

1 reference

Europe PubMed Central

26 July 2017

Philippe Moreau

26

object named as

Philippe Moreau

1 reference

Europe PubMed Central

26 July 2017

Wieslaw Jedrzejczak

7

object named as

Wieslaw Wiktor Jedrzejczak

1 reference

Europe PubMed Central

26 July 2017

16

object named as

Kwee Yong

1 reference

Europe PubMed Central

26 July 2017

Jamie D Cavenagh

19

object named as

Jamie D Cavenagh

1 reference

Europe PubMed Central

26 July 2017

29

object named as

Joan Bladé

1 reference

Europe PubMed Central

26 July 2017

2

object named as

Vânia T M Hungria

1 reference

Europe PubMed Central

26 July 2017

Thanyaphong Na Nakorn

9

object named as

Thanyaphong Na Nakorn

1 reference

Europe PubMed Central

26 July 2017

Noppadol Siritanaratkul

10

object named as

Noppadol Siritanaratkul

1 reference

Europe PubMed Central

26 July 2017

Robert Schlossman

14

object named as

Robert L Schlossman

1 reference

Europe PubMed Central

26 July 2017

23

object named as

Lugui Qiu

1 reference

Europe PubMed Central

26 July 2017

32

object named as

Peter Gimsing

1 reference

Europe PubMed Central

26 July 2017

Claudia Corrado

42

object named as

Claudia Corrado

1 reference

Europe PubMed Central

26 July 2017

Bourras-Rezki Bengoudifa

43

object named as

Bourras-Rezki Bengoudifa

1 reference

Europe PubMed Central

26 July 2017

Florence Binlich

44

object named as

Florence Binlich

1 reference

Europe PubMed Central

26 July 2017

Jonathan L Kaufman

34

object named as

Jonathan L Kaufman

1 reference

Europe PubMed Central

26 July 2017

30

object named as

WenMing Chen

1 reference

Europe PubMed Central

26 July 2017

Jesús San Miguel

1

object named as

Jesús F San-Miguel

1 reference

Europe PubMed Central

26 July 2017

4

object named as

Meral Beksac

1 reference

Europe PubMed Central

26 July 2017

author name string

Sung-Soo Yoon

3

1 reference

Europe PubMed Central

26 July 2017

Andreas Günther

8

1 reference

Europe PubMed Central

26 July 2017

Suporn Chuncharunee

12

1 reference

Europe PubMed Central

26 July 2017

Je-Jung Lee

13

1 reference

Europe PubMed Central

26 July 2017

Tatiana Shelekhova

15

1 reference

Europe PubMed Central

26 July 2017

Daryl Tan

17

1 reference

Europe PubMed Central

26 July 2017

Tontanai Numbenjapon

18

1 reference

Europe PubMed Central

26 July 2017

Jian Hou

20

1 reference

Europe PubMed Central

26 July 2017

Richard LeBlanc

21

1 reference

Europe PubMed Central

26 July 2017

Stefano Pulini

25

1 reference

Europe PubMed Central

26 July 2017

Darrell White

28

1 reference

Europe PubMed Central

26 July 2017

Ljupco Veskovski

36

1 reference

Europe PubMed Central

26 July 2017

Sang Kyun Sohn

37

1 reference

Europe PubMed Central

26 July 2017

Ming-Chung Wang

38

1 reference

Europe PubMed Central

26 July 2017

Jae Hoon Lee

39

1 reference

Europe PubMed Central

26 July 2017

publication date

18 September 2014

1 reference

Europe PubMed Central

26 July 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

15

1 reference

Europe PubMed Central

26 July 2017

1195-1206

1 reference

Europe PubMed Central

26 July 2017

11

1 reference

Europe PubMed Central

26 July 2017

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of response endpoints with survival outcomes in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970440-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70440-1

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417762&oldid=2010746747"